ABY-071

ABY-071 is a radiotherapeutic candidate aimed at tumor cells that express B7-H3, regardless of their position in the body.

B7-H3 is a cell surface immunomodulatory glycoprotein overexpressed by many different types of cancers, whereas its expression is low in most normal organs and tissues. This makes it a promising target for cancer therapies. B7-H3 inhibits tumor specific immune responses and promotes tumor cell proliferation and invasion. High B7-H3 expression is generally associated with poor prognosis.

ABY-071 is labeled with the radioisotope lutetium-177, which emits cytotoxic beta radiation exerting irreversible damage to the tumor cells upon binding. Initial preclinical biodistribution results have been generated and a candidate drug was selected in 2025.